Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
7.00
+0.27 (4.01%)
May 20, 2025, 4:00 PM - Market closed
Atara Biotherapeutics Revenue
Atara Biotherapeutics had revenue of $98.15M in the quarter ending March 31, 2025, with 258.77% growth. This brings the company's revenue in the last twelve months to $199.73M, up 475.53% year-over-year. In the year 2024, Atara Biotherapeutics had annual revenue of $128.94M with 1,404.02% growth.
Revenue (ttm)
$199.73M
Revenue Growth
+475.53%
P/S Ratio
0.31
Revenue / Employee
$1,305,438
Employees
153
Market Cap
41.01M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ATRA News
- 4 days ago - Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors - Business Wire
- 5 days ago - Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress - Business Wire
- 5 days ago - Atara Biotherapeutics Announces Pricing of $16 Million Offering - Business Wire
- 15 days ago - Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel) - Business Wire
- 2 months ago - Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress - Business Wire
- 2 months ago - The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation - Accesswire
- 3 months ago - The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation - Accesswire
- 3 months ago - Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws - PRNewsWire